Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk stock surged over 50% in 2023, in large part because of its medications used in weight loss. While the company has a solid foundation in the diabetes and obesity markets, competition is rising.

Will Novo Nordisk Be a $1 Trillion Company by 2030?

Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Novo Nordisk (NVO) This Earnings Season?

Novo Nordisk has formed a four-weeks-tight pattern ahead of fourth-quarter results on Wednesday.

Leader In Weight Loss Drugs Nears Buy Point With Earnings Due This Week

Franklin Resources

Copa Hlds

Carpenter Technology

Janus Henderson Group

We have narrowed our search to five momentum stocks that are poised to beat on earnings results next week. These are: BEN, NVO, CPA, CRS, JHG.

5 Momentum Stocks to Buy Ahead of Earnings Results

Novo Nordisk (NVO) reachead $105.49 at the closing of the latest trading day, reflecting a -1.37% change compared to its last close.

Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts

Novo Nordisk's weight loss drug, Wegovy, earned $1.38 billion last quarter and is projected to share a large piece of the growing weight-loss drug market. Despite its market dominance, Novo faces challenges in affordability, competition (like Eli Lilly's Zepbound), and sustainable obesity treatments. Novo Nordisk's recent financial performance exceeds expectations, indicating strong market confidence and robust growth projections.

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Hims & Hers Health

UnitedHealth Group

Novo Nordisk has a long runway with its GLP-1 RA products. Hims & Hers Health is rapidly picking up patients.

Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money

CRISPR Therapeutics

Eli Lilly

CRISPR Therapeutics stock has room to run higher with the biotech's first therapy on the market. Eli Lilly is now the world's biggest drugmaker and has multiple growth drivers.

3 High-Flying Stocks That Could Soar Even More in 2024

Arcos Dorados Hlds

EnerSys

ARCO, NVO and ENS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 19, 2024.

Best Growth Stocks to Buy for January 19th

Novo Nordisk (NVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Novo Nordisk (NVO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Its most important therapeutic area should help it deliver excellent financial results. The drugmaker is expanding into other fields to diversify its portfolio of medicines.

Is Novo Nordisk Stock a Buy Now?

Assurant

Patria Investments

NVO, AIZ and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 16, 2024.

Best Growth Stocks to Buy for January 16th

GlaxoSmithKline

Sanofi

Drug stocks GSK, Sanofi, Merck KGaA, and Novartis look set for a good year on strong cash flows and attractive valuations, says UBS.

4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn't One.

Clinical weight-loss medications have been making headlines. GLP-1 drugs like Novo Nordisk A/S NYSE: NVO owned Ozempic and Wegovy and Eli Lilly and Co. NYSE: LLY owned Mounjaro and Zepbound continue to see demand outstrip supply.

2 biotechs with promising weight-loss drugs coming

Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is Why Growth Investors Should Buy Novo Nordisk (NVO) Now

Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Novo Nordisk (NVO) Is Up 2.45% in One Week: What You Should Know

It's fair to say the pharmaceutical landscape is experiencing a seismic shift due to the burgeoning success of drugs such as Ozemic, the diabetic treatment that has now morphed into a super-blockbuster treatment for weight loss, which goes by the alternate name of Wegovy. Developed by Novo Nordisk (NYSE:NVO), Ozempic has transformed the Danish company from an also-ran to Europe's largest drug company by market capitalisation.

Ozempic has transformed Novo Nordisk, but who is next with a me-too weight loss drug?

Novo Nordisk stock remains a great buy at every dips, thanks to its expanding 2030 TAM to $150B, highly profitable growth trend, and improving balance sheet. Readers must also note that its growing oral/injectable diabetes/obesity pipelines, with its late stage candidates being highly promising. Combined with the excellent patient adherence rate and raised guidance/estimates, we believe that consumers' vote of confidence may bring about NVO's sustained top/bottom line growth and shareholder returns.

Taking Novo Nordisk To The Next Level

Stifel has identified Novo Nordisk (NYSE:NVO), Merck KGaA, and Sandoz as top picks in the European pharmaceutical sector for the first quarter of 2024, according to its recent research note. Novo Nordisk is highlighted for its exceptional growth outlook, with analysts anticipating over 20% growth in 2024, distinct from its big pharma peers.

Have Novo Nordisk shares got further to go? This investment bank has its say

Novo Nordisk makes the popular weight treatments Ozempic, Wegovy, Saxenda, and Rybelsus. Success of each of these medications has fueled unprecedented growth for the Danish company.

After Surging 53% in 2023, This Pharmaceutical Stock Might Be About to Crash. Here's Why I'm Probably Wrong

Vertex Pharmaceuticals

Eli Lilly is growing by leaps and Zepbounds. Novo Nordisk is just getting warmed up after delivering a 53% gain last year.

3 Unstoppable Stocks to Buy in 2024

Ozempic was a big factor behind Novo Nordisk's success last year, but not the biggest growth driver. The drugmaker had a lot of good news that boosted its stock price in 2023.

Why Novo Nordisk Stock Soared 53% in 2023 (Hint: It Wasn't Just Ozempic)

Novo Nordisk said on Friday it resumed shipments of weight loss drug Wegovy in the 1.7 milligram dose in early January, following a short-term stock-out in the U.S. in mid-December last year.

Novo Nordisk resumes shipments of Wegovy 1.7 mg dose in US

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Should You Invest in Novo Nordisk (NVO) Based on Bullish Wall Street Views?

Amgen

AstraZeneca

The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.

News for Novo Nordisk Stock (NVO)